Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306 (C-13/N-15)
Drug: BI 409306

First Posted Date: 2018-04-23

Last Posted Date: 2024-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9

Registration Number: NCT03505151

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Digital Auscultation Test - IPF Data Collection

Phase 4

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Device: Littmann ®

First Posted Date: 2018-04-19

Last Posted Date: 2020-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 274

Registration Number: NCT03503188

Locations: 🇩🇪
Klinikum Chemnitz gGmbH, Chemnitz, Germany
🇩🇪
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany
🇩🇪
Fachkrankenhaus Coswig GmbH, Coswig, Germany

and more 7 locations

This Study in Healthy Men Tests How the Body Takes up BI 1467335

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1467335
Drug: BI 1467335 (C-14) intravenous solution

First Posted Date: 2018-03-30

Last Posted Date: 2021-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT03483506

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 730460

First Posted Date: 2018-03-29

Last Posted Date: 2022-08-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT03483077

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

Phase 2

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Placebo
Drug: Spesolimab

First Posted Date: 2018-03-29

Last Posted Date: 2021-06-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 98

Registration Number: NCT03482635

Locations: 🇨🇦
University of Manitoba - Health Sciences Centre, Winnipeg, Manitoba, Canada
🇷🇺
FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien., Irkutsk, Russian Federation
🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany

and more 51 locations

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms
Non-squamous, Non-Small-Cell Lung Cancer

Interventions: Drug: BI 836880
Drug: ezabenlimab

First Posted Date: 2018-03-16

Last Posted Date: 2024-12-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 252

Registration Number: NCT03468426

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 40 locations

Empa PASS on Urinary Tract Malignancies

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: empagliflozin
Drug: DPP-4 inhibitors

First Posted Date: 2018-03-13

Last Posted Date: 2024-11-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 98000

Registration Number: NCT03464045

Locations: 🇬🇧
United Kingdom Clinical Practice Research Datalink (CPRD), London, United Kingdom
🇸🇪
The Swedish prescribed drug register, Stockholm, Sweden
🇫🇮
The National Register Data, Helsinki, Finland

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2018-02-28

Last Posted Date: 2020-12-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 315

Registration Number: NCT03448406

Locations: 🇺🇸
Cox Medical Center South, Springfield, Missouri, United States
🇺🇸
Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
Acacia Medical Research Institute,LLC, Sugar Land, Texas, United States

and more 104 locations

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Empagliflozin

First Posted Date: 2018-02-28

Last Posted Date: 2020-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 312

Registration Number: NCT03448419

Locations: 🇺🇸
University Of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
The Center for Clinical Trials, Inc., Saraland, Alabama, United States

and more 105 locations

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: BI 907828

First Posted Date: 2018-02-28

Last Posted Date: 2024-12-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 267

Registration Number: NCT03449381

Locations: 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States

and more 24 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy